Cormica Bradford Successfully Completes FDA GMP Surveillance Inspection
Cormica is pleased to announce that our Bradford analytical laboratory has successfully completed a two-day GMP surveillance inspection by the United States Food and Drug Administration (FDA), carried out in September 2025. The inspection concluded with no Form 483 observations and a final classification of No Action Indicated.
This was the first FDA visit to Cormica Bradford since 2018 and reflects the increasing number of pharmaceutical APIs and finished products we support for the US market. The inspection examined our contract analytical research and testing activities, with a particular focus on data that is directly relevant to FDA applications. Being named in these submissions underlines the trust clients place in our work and the critical role our scientists play in ensuring product quality and patient safety.
Throughout the inspection, the Bradford team showed the strengths that define Cormica. Their attention to detail, collaboration across functions, and clear sense of ownership supported a smooth and transparent review process. These behaviours reflect how we work every day as we help clients navigate complex development pathways and bring safe, effective products to patients worldwide.
Cormica Bradford is one of Cormica’s principal centres for analytical chemistry, operating across eight dedicated buildings within the University of Bradford’s science park. The site specialises in materials characterisation, method development and validation, solid state analysis, particulate and impurity assessment, and stability studies that support pharmaceutical products throughout development and into commercial lifecycle.
Caroline German, PhD FRSC
Cormica Bradford Operations Director
“This is a tremendous milestone for Cormica Bradford. Achieving a successful inspection with no actions is a powerful testament to our robust procedures and the dedication, skill, and technical excellence of our scientists. I couldn’t be prouder of the Bradford team and the unwavering commitment to quality they demonstrate every day.”
Passing this FDA inspection is an important milestone for the Bradford team and reinforces Cormica’s mission to improve patients’ lives by providing comprehensive testing services, enabling clients to launch and release their products safely and rapidly across the world.
The successful outcome follows recent FDA inspections across other parts of the Cormica network, including MET in 2024 and TPM Labs and Focus Laboratories earlier in 2025. Together, these results demonstrate the consistency of our quality systems and our commitment to global regulatory expectations.
For more information about our analytical chemistry capabilities or support for your US regulatory submissions, please contact sales@cormica.com.
Laboratories near you, supporting global product success
With accredited laboratories in the UK, EU and US, we support pharmaceutical, medical device and combination product manufacturers worldwide. Local support combined with global quality, delivered by teams who understand your regulatory requirements.
Contact Us
Ready to take the next step? We’d love to hear from you. Contact us today to discuss your testing needs and find out how Cormica can help you achieve your goals.
Our Clients’ Experiences
